Investigation of monoclonal antibody therapy with conventional and high-dose treatment: current clinical trials.
The approval of rituximab for recurrent low-grade or follicular B-cell malignancy has created marked interest in CD20-targeted therapy in a wide range of patients, including those who have not previously been treated or who have other tumor types. Due to anti-CD20's single-agent activity and nonoverlapping toxicity with conventional treatments, combination therapy incorporating monoclonal antibodies has become the focus of intense investigation. Phase 2 studies indicate that rituximab can be administered safely with conventional and high-dose chemotherapy regimens commonly used to treat non-Hodgkin's lymphoma (NHL); however, it has not been established whether combined treatment results in increased efficacy. Randomized, prospective phase 3 investigations of rituximab in combination with chemotherapy are currently ongoing. Investigators are encouraged to evaluate and enroll as many patients as possible in these and other important trials.
Horning
J S
JS
Department of Medicine, Stanford University School of Medicine, CA, USA.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016393:Lymphoma, B-Cell / Q000628:therapy; D008224:Lymphoma, Follicular / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000628:therapy*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab